[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 895
Citations 0
Comment & Response
September 1, 2015

Assessing Eligibility for Anticoagulation After Diagnosis of Atrial Fibrillation

Author Affiliations
  • 1Dipartimento di Oncologia, Ematologia e Malattie dell’Apparato Respiratorio, Azienda Ospedaliero-Universitaria, Modena, Italy
  • 2Agenzia Sanitaria e Sociale, Regione Emilia-Romagna, Bologna, Italy
JAMA. 2015;314(9):949. doi:10.1001/jama.2015.8992

To the Editor Some points in the review by Drs Lip and Lane1 about stroke prevention in atrial fibrillation deserve further discussion.

We disagree with the suggestion of using the score for sex, age, medical history, treatment, tobacco, and race (SAMe-TT2R2) as a tool for assessing patients’ eligibility for treatment with a non–vitamin K antagonist oral anticoagulant (NOAC). Use of the SAMe-TT2R2 score in everyday clinical practice would require great caution and further evaluation, especially considering that it has been validated as a tool for predicting poor international normalized ratio (INR) control rather than the effect of anticoagulation strategies on clinical outcomes in real-world practice.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×